GFAP and amyotrophic lateral sclerosis: However, there was no significant difference in GFAP+ cell area between TgSOD1-Cromolyn and TgSOD1-Vehicle groups (p = 0.923), suggesting that cromolyn treatment does not impact astrogliosis in the TgSOD1 mouse model of ALS.